Key result
Indobufen-based DAPT linked to ~42% fewer major GI events vs aspirin in post-PCI ACS.
Why the study?
Data on the efficacy and safety of long-term indobufen use as an alternative to aspirin in ACS patients with gastrointestinal damage undergoing PCI are limited.
Does indobufen-based DAPT reduce adverse gastrointestinal events compared to aspirin-based DAPT in ACS patients with a history of gastrointestinal damage undergoing PCI?
Does indobufen-based DAPT reduce adverse gastrointestinal events compared to aspirin-based DAPT in ACS patients with a history of gastrointestinal damage undergoing PCI?
In ACS patients with prior gastrointestinal damage undergoing PCI, indobufen-based DAPT significantly reduces adverse gastrointestinal events compared to aspirin-based DAPT without increasing the risk of major adverse cardiovascular events.
Purpose Indobufen, an alternative to aspirin in acute coronary syndrome (ACS) patients with gastrointestinal damage undergoing percutaneous coronary intervention (PCI), has limited data on its efficacy and safety in long-term use. This study compared indobufen-based dual antiplatelet therapy (DAPT) to aspirin-based DAPT in such patients. Methods We retrospectively analyzed 255 PCI patients with a history of gastrointestinal damage, divided into indobufen (n = 90) and aspirin (n = 165) groups. We defined the composite of major adverse gastrointestinal events as a composite endpoint event of dyspepsia, peptic ulcer disease and gastrointestinal hemorrhage. Concurrently, the composite of clinically significant adverse gastrointestinal events has been designated as a composite endpoint comprising peptic ulcer disease and gastrointestinal hemorrhage. Results Indobufen significantly reduced the incidence of the composite of major adverse gastrointestinal events (25.6% vs 39.4%, HR = 0.58, 95% CI:0.36–0.94, P = 0.026) and the composite of clinically significant adverse gastrointestinal events (18.9% vs 33.3%, HR = 0.53, 95% CI:0.30–0.90, P = 0.020) compared to aspirin. There was no significant difference in major adverse cardiovascular events (MACE) incidence between the two groups (4.4% vs 6.7%, P = 0.400). Conclusion In conclusion, compared with aspirin, the use of indobufen-based DAPT was associated with a lower incidence of the composite of major adverse gastrointestinal events, which was mainly driven by a reduction in the clinical symptoms and an improvement in quality of life.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question. Indobufen-based DAPT reduced major adverse GI events by 42% (25.6% vs 39.4%, HR=0.58) compared to aspirin in ACS patients with GI damage post-PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: